You will be shown a paragraph from a biomedical research article. Your task is to extract all drug combinations appearing in a specific sentence within in the paragraph. Each drug combination should be assigned to one of the following three categories:

- POS: Indicates a positive interaction between the drugs in the combination; for instance, drugs that have an additive or synergistic effect.
- NEG: Indicates a negative interaction between the drugs in the combination; for instance, combining these drugs might result in adverse side effects, or might reduce their efficacy.
- COMB: Indicates that the drugs are given in combination, but the type of interaction between the drugs cannot be determined based on the provided context.

Please format your answer as a json array. Each entry in the array should itself be an array formatted as [<drug_1>, <drug_2>, ..., <drug_n>, <category>] where <category> is one of the three categories listed above and <drug_1>, ..., <drug_n> are drug names copied verbatim from the input sentence. Different combinations may involve different numbers of drugs; in other words, the `n` in <drug_n> may vary.

As an example, the following output describes two extracted drug combinations; one between two drugs, and one between three drugs:

[["artesunate", "artemether", "COMB"], ["Nifedipine", "Labetalol", "Prazosin", "POS"]]

The paragraph and specific sentence are below. You should only extract relationships expressed in the specific sentence; the paragraph is provided for context.

In your output, return only the json array and no other text. If no drug combinations appear, return an empty array `[]`.

paragraph: [Treatment of chronic hepatitis C in human immunodeficiency virus infected patients]. Treatment of HCV infection offers the possibility of viral eradication, thus every person with a detectable HCV viral load is a candidate for treatment. Treatment is recommended to all HCV/HIV co-infected patients with: 1) repeatedly elevated aminotransferase levels; 2) F2 stage of liver fibrosis or higher, regardless of alanine aminotransferase values; and 3) more than 200 CD4+ lymphocytes per microL of blood. Treatment with a combination of pegylated interferon and weight-based ribavirin (1000 mg/day if < 75 kg and 1200 mg/day if > 75 kg) is recommended. Pegylated interferon is used as 180 microg for the alfa-2a form and 1.5 mg/kg for the alfa-2b form once weekly subcutaneously. HCV RNA should be measured after 4 weeks of treatment, and later as needed, in weeks 12, 24, 48 or 72. For evaluation of a sustained virologic response, HCV RNA should be measured 24 weeks after the end of treatment. Treatment duration for patients who have a rapid viral response (undetectable levels of HCV RNA after 4 weeks of treatment) is 24 weeks (genotypes 2 and 3) or 48 weeks (genotypes 1 and 4). For patients without a rapid virologic response, but with an adequate response after 12 and 24 weeks, we generally recommend treatment for 48 weeks. Treatment discontinuation is recommended for patients with < 2 log viral load decline after 12 weeks or with a detectable viral load after 24 weeks of treatment. In HCV genotype 1 infection and F3 or F4 liver fibrosis , treatment with boceprevir or telaprevir in addition to pegylated interferon and ribavirin is recommended . In case of persistent HCV replication during therapy stopping rules should be applied.

sentence: In HCV genotype 1 infection and F3 or F4 liver fibrosis , treatment with boceprevir or telaprevir in addition to pegylated interferon and ribavirin is recommended .
[["boceprevir", "pegylated interferon", "ribavirin", "POS"], ["telaprevir", "pegylated interferon", "ribavirin", "POS"]]